Authors

Latest:

Oncology Fellow Focuses on Compassionate End-of-Life Care

Due to the misconception surrounding "hospice," many patients with cancer use excess hospital care and intensive care services at the end of life.

Jennifer Yuchen Shih, MD,

Latest:

Dr. Shih on Treating Lobular vs Ductal Breast Cancers

Jennifer Yuchen Shih, MD, a medical oncologist at Fox Chase Cancer Center, discusses the ABCSG-8 and BIG 1-98 studies and their impacts on the treatment of lobular breast cancer compared to ductal breast cancers.

Jenny C. Chang, MD

Latest:

Dr. Chang on Genomic Testing in Breast Cancer

Jenny C. Chang, MD, director of the Methodist Cancer Center at Houston Methodist Hospital, discusses genomic testing in breast cancer.

Jenny Pincus, MD

Latest:

Dr. Pincus on Classifying HER2+ Tumors in Breast Cancer

Jenny Pincus, MD, assistant professor of pathology, Northwestern University, Feinberg School of Medicine, discusses the classification of HER2-positive tumors in patients with breast cancer.

Jenny Powers, PhD

Latest:

Combinations With Abemaciclib Show Long-Term Disease Control in Advanced Breast Cancer

Abemaciclib plus tamoxifen, trastuzumab, or one of many endocrine-based therapies demonstrated significant antitumor activity and clinical benefit in patients with advanced breast cancer.

Jens Hillengass, MD

Latest:

Cellular Therapy Strategies Offer the Prospect of Deep Remissions for Multiple Myeloma

The FDA approval of the first chimeric antigen receptor T-cell therapy in March 2021 for the treatment of relapsed/refractory multiple myeloma represents a significant advance.

Jens Huober, MD

Latest:

Dr. Houber on the De-Escalation of Treatments for Breast Cancer

Jens Huober, MD, professor of gynecologic oncology, Ulm University Hospital, discusses the de-escalation of treatments for patients with breast cancer.

Jerald P. Radich, MD

Latest:

Dr. Radich on the Impact of MRD on Survival Outcomes in AML

Jerald Radich, MD, discusses the impact of minimal residual disease on survival outcomes in patients with acute myeloid leukemia.

Jeremie Calais, MD, PhD

Latest:

Dr Calais on Controversies in the Treatment of Patients With Prostate Cancer

Jeremie Calais, MD, PhD, discusses controversies and unresolved questions in the treatment of patients with prostate cancer.

Jeremy Abramson, MD

Latest:

Dr Abramson on the Efficacy of Second-line Liso-cel Vs SOC in Relapsed/Refractory LBCL

Jeremy Abramson, MD, discusses the efficacy data of second-line lisocabtagene maraleucel vs standard-of-care salvage chemotherapy followed by autologous stem cell transplant from the phase 3 TRANSFORM trial done in patients with relapsed/refractory large B-cell lymphoma.

Jeremy Segal, MD, PhD

Latest:

Dr. Segal on Next-Generation Sequencing for Lung Cancer

Jeremy Segal, MD, PhD, discusses the use of next-generation sequencing for patients with lung cancer.

Jeremy Slade Abramson, MD

Latest:

Dr. Abramson Discusses TRANSCEND in Relapsed/Refractory B-Cell Lymphomas

Jeremy Slade Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the updated results of the TRANSCEND study in patients with relapsed/refractory b-cell lymphomas.

Jeri L. Ashley, RN, Baptist Memorial

Jerome G. Kim, MD

Latest:

Dr. Jerome Kim on Geriatric Assessment Tool for Older Patients With Cancer

Jerome G. Kim, MD, medical oncologist, hematologist, Kaiser Permanente, discusses the feasibility of an assessment tool for older adults with cancer using web-based platforms.

Jerome Galon, PhD

Latest:

Next Steps for Immunoscore in Oncology

Jerome Galon, PhD, research director, French Institute of Health and Medical Research, discusses next steps with Immunoscore in oncology.

Jerry Conway

Latest:

The Role of Companion Diagnostic Testing in Payer Decision Making

Companion diagnostics can enable significant improvements in safety, efficacy, outcomes, and cost-effectiveness associated with many existing and new therapies.

Jerry Lanchbury, PhD

Latest:

Jerry Lanchbury, PhD, Describes Myriad's HRD Test

Jerry Lanchbury, PhD, Chief Scientific Officer, Myriad Genetics, Inc., describes the HRD (homologous recombination deficiency) test.

Jerry W. Mitchell, MD

Latest:

Dr. Mitchell on Clinical Trials Exploring Medical Marijuana for Patients With Cancer

Jerry W. Mitchell, MD, oncologist, Zangmeister Cancer Center, discusses clinical trials exploring medical marijuana for patients with cancer.

Jesper Andersen, PhD

Latest:

Challenges Facing the Future of Cholangiocarcinoma

Jesper Andersen, PhD, associate professor, Biotech and Innovation Centre, University of Copenhagen, discusses the challenges facing the future treatment of patients with cholangiocarcinoma.

Jessica Bauman, MD

Latest:

Dr. Bauman on Treatments for Patients With BRAF-Mutant NSCLC

Jessica Bauman, MD, assistant professor, Department of Hematology/Oncology, associate program director, Hematology/Oncology Fellowship Training Program, Fox Chase Cancer Center, discusses treatments for patients with BRAF-mutant non–small cell lung cancer (NSCLC).